ロード中...
Will FLT3 Inhibitors Fulfill Their Promise in AML?
PURPOSE OF REVIEW: FLT-3 mutations in Acute Myeloid Leukemia (AML) have been brought from discovery in the early 1990's to clinical targeting in the last ten years. Despite several promising leads in pre-clinical models, no agent has yet been approved for clinical use. Here we will review the d...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4142569/ https://ncbi.nlm.nih.gov/pubmed/24468836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOH.0000000000000022 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|